期刊
JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS
卷 35, 期 10, 页码 615-619出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JXX.0000000000000890
关键词
Diabetes innovation; diabetes technology; insulin pump therapy; multiple daily injections; type 2 diabetes
This study aimed to measure the change in HgbA1c in patients with type 2 diabetes (T2D) after switching therapy from multiple daily injections (MDI) to continuous subcutaneous insulin infusion through insulin pump therapy (IPT). The results showed a statistically significant reduction in mean HgbA1c levels from 9.6% to 7.6% after using IPT.
Background:More than 35 million Americans live with type 2 diabetes (T2D), resulting in the need for newer strategies and technologies to manage the disease. Insulin pump therapy (IPT) has historically been reserved for type 1 diabetes, although emerging data demonstrates improved glucose outcomes for patients with T2D using IPT.Purpose:To measure the change in HgbA1c in patients with T2D after changing therapy from multiple daily injections (MDI) to continuous subcutaneous insulin infusion through IPT.Methodology:A retrospective comparison study was conducted by reviewing the electronic medical record of patients with T2D, older than 18 years, who had been on multiple daily insulin injections for at least 1 year, followed by IPT for at least 1 year.Results:One hundred seventy-one patients met the inclusion criteria. There was a statistically significant reduction in mean HgbA1c from 9.6% to 7.6%.Conclusion:Insulin pump therapy may result in lower HgbA1c levels for T2D not at goal on MDI.Implications:Patients on multiple daily insulin injections who are not at goal should be considered for IPT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据